Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Tuberculosis: the story after the Primer

Collaboration between authors and journal staff can contribute to expand the reach of Primers, including to areas where they would be most useful.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. Pai, M. et al. Tuberculosis. Nat. Rev Dis Primers 2, 1–23 (2016).

    Article  Google Scholar 

  2. World Health Organization. Global Tuberculosis Report 2019.

  3. Van Der Meeren, O. et al. Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis. N. Engl. J. Med. 379, 1621–1634 (2018).

    Article  Google Scholar 

  4. US Food & Drug Administration. FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs. (2019).

  5. Swindells, S. et al. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N. Engl. J. Med. 380, 1001–1011 (2019).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Madhukar Pai.

Ethics declarations

Competing interests

The author declares no competing interests.

Additional information

Related links

Nature Microbiology Community blog:



Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Pai, M. Tuberculosis: the story after the Primer. Nat Rev Dis Primers 6, 29 (2020).

Download citation

  • Published:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing